Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis

New England Journal of Medicine

Volumn 366, Issue 13, 2012, Pages 1190-1199

  Leonardi, Craig ^a   Matheson, Robert ^b   Zachariae, Claus ^c   Cameron, Gregory ^d   Li, Linda ^e   Edson Heredia, Emily ^d   Braun, Daniel ^d   Banerjee, Subhashis ^d  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Oregon Medical Research Center PC   (United States)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^d ELI LILLY AND COMPANY   (United States)

^e PharmaNet/i3   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DESOXIMETASONE; EMOLLIENT AGENT; IXEKIZUMAB; PLACEBO; SALICYLIC ACID; STEROID;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTERIAL INFECTION; BASAL CELL CARCINOMA; BILIRUBIN BLOOD LEVEL; BODY SURFACE; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; CONTACT DERMATITIS; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG INDUSTRY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYCOSIS; NEUTROPENIA; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PSORIASIS SEVERITY INDEX; PSORIASIS VULGARIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; TH17 CELL; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VISUAL ANALOG SCALE;

EID: 84859073115     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1109997     Document Type: Article

References (28)

1. Kurd SK, Gelfand JM. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004. J Am Acad Dermatol 2009;60:218-24. [Erratum, J Am Acad Dermatol 2009;61:507.]
2. Fitch E, Harper E, Skorcheva I, Kurtz SE, Blauvelt A. Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines. Curr Rheumatol Rep 2007;9: 461-7. (Pubitemid 350305203)
3. Kikly K, Liu L, Na S, Sedgwick JD. The IL-23/Th(17) axis: therapeutic targets for autoimmune inflammation. Curr Opin Immunol 2006;18:670-5. [Erratum, Curr Opin Immunol 2007;19:111.] (Pubitemid 44635178)
4. Arican O, Aral M, Sasmaz S, Ciragil P. Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm 2005;2005:273-9.
5. Li J, Chen X, Liu Z, Yue Q, Liu H. Expression of Th17 cytokines in skin lesions of patients with psoriasis. J Huazhong Univ Sci Technolog Med Sci 2007;27:330-2.
6. Fredriksson T, Pettersson U. Severe psoriasis -oral therapy with a new retinoid. Dermatologica 1978;157:238-44. (Pubitemid 8387357)
7. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19:210-6. (Pubitemid 24194579)
8. Kimball AB, Krueger GG, Woolley JM. Minimal important differences for the dermatology life quality index (DLQI) in psoriasis patients. Presented at the meeting of the American Academy of Dermatology, New York, July 28-August 1, 2004. (Poster.)
9. Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. August 9, 2006 (http://ctep.cancer.gov/protocol Development/electronic- applications/docs/ctcaev3.pdf).
10. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept asmonotherapy in patients with psoriasis. N Engl J Med 2003; 349:2014-22.
11. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, doubleblind, placebo-controlled trial (PHOENIX 1). Lancet 2008;371:1665-74. [Erratum, Lancet 2008;371:1838.] (Pubitemid 351671883)
12. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008;371:1675-84. (Pubitemid 351671884)
13. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005;366:1367-74. (Pubitemid 41443403)
14. Kolls JK, Lindén A. Interleukin-17 family members and inflammation. Immunity 2004;21:467-76. (Pubitemid 39370503)
15. Tyring S, Mendoza N, Appell M, et al.A calcipotriene/betamethasone dipropionate two-compound scalp formulation in the treatment of scalp psoriasis in Hispanic/ Latino and Black/African American patients: results of the randomized, 8-week, double-blind phase of a clinical trial. Int J Dermatol 2010;49:1328-33.
16. van de Kerkhof PC, Franssen ME. Psoriasis of the scalp: diagnosis and management. Am J Clin Dermatol 2001;2:159-65. (Pubitemid 32492328)
17. Rigopoulos D, Gregoriou S, Lazaridou E, et al. Treatment of nail psoriasis with adalimumab: an open label unblinded study. J Eur Acad Dermatol Venereol 2010; 24:530-4.
18. Krueger J, Fretzin S, Farinas M, et al. Interleukin-17A isan essential cytokine to sustain pathogenic cell activation and inflammatory gene circuits in psoriasis vulgaris. Br J Dermatol 2011;165(6):e6.
19. Chan JR, Blumenschein W, Murphy E, et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med 2006;203:2577-87. (Pubitemid 44833335)
20. Laan M, Cui ZH, Hoshino H, et al. Neutrophil recruitment by human IL-17 via C-X-C chemokine release in the airways. J Immunol 1999;162:2347-52. (Pubitemid 29288861)
21. Starnes T, Broxmeyer HE, Robertson MJ, Hromas R. Cutting edge: IL-17D, anovel member of the IL-17 family, stimulates cytokine production and inhibits hemopoiesis. J Immunol 2002;169:642-6. (Pubitemid 34753417)
22. Numasaki M, Fukushi J, Ono M, et al. Interleukin-17 promotes angiogenesis and tumor growth. Blood 2003;101:2620-7. (Pubitemid 36857622)
23. Ruddy MJ, Wong GC, Liu XK, et al. Functional cooperation between interleukin-17 and tumor necrosis factor-alpha is mediated by CCAAT/enhancer-binding protein family members. J Biol Chem 2004;279:2559-67. (Pubitemid 38114241)
24. Albanesi C, Scarponi C, Cavani A, Federici M, Nasorri F, Girolomoni G. Interleukin-17 isproduced by both Th1 and Th2 lymphocytes, and modulates interferongamma- and interleukin-4-induced activation of human keratinocytes. J Invest Dermatol 2000;115:81-7. (Pubitemid 30470196)
25. Homey B, Dieu-Nosjean MC, Wiesenborn A, et al. Up-regulation of macrophage inflammatory protein-3 alpha/ CCL20 and CC chemokine receptor 6 in psoriasis. J Immunol 2000;164:6621-32. (Pubitemid 30408849)
26. Chiricozzi A, Guttman-Yassky E, Suárez-Fariñas M, et al. Integrative responses toIL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol 2011;131:677-87.
27. Hueber W, Patel DD, Dryja T, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2010;2:52ra72.
28. Papp KA, Leonardi C, Menter A, et al. Brodalumab, ananti-interleukin-17- receptor antibody for psoriasis. N Engl J Med 2012;366:1181-9.